Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: Short report from a developing country

Leukemia and Lymphoma

Volumn 55, Issue 9, 2014, Pages 2109-2113

  Iqbal, Javaid ^a   Ali, Zafar ^b   Khan, Aruj Un Nisa ^c   Aziz, Zeba ^c  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b KING FAHAD MEDICAL CITY   (Saudi Arabia)

^c ALLAMA IQBAL MEDICAL COLLEGE   (Pakistan)

Author keywords

Chronic myeloid leukemia; Developing country; Imatinib mesylate; Outcomes; Pregnancy

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; ADVERSE OUTCOME; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONGENITAL MALFORMATION; COUNSELING; DRUG WITHDRAWAL; FEMALE; HUMAN; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PHILADELPHIA CHROMOSOME POSITIVE CELL; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PREMATURITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; QUALITY OF LIFE; YOUNG ADULT; ADOLESCENT; DEVELOPING COUNTRY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BENZAMIDES; DEVELOPING COUNTRIES; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREGNANCY OUTCOME; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906070267     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.866662     Document Type: Article

References (15)

1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
2. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
3. Mahon F-X, R é a D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035.
4. S chwartzberg P L, R obertson E J, G off SP. Targeted gene disruption of the endogenous c-abl locus by homologous recombination with DNA encoding a selectable fusion protein. Proc Natl Acad Sci USA 1990; 87: 3210-3214.
5. Schwartzberg PL, Stall AM, Hardin JD, et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell 1991; 65: 1165-1175.
6. Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 2007; 27: 241-243.
7. Eskander RN, Tarsa M, Herbst KD, et al. Chronic myelocytic leukemia in pregnancy: a case report describing successful treatment using multimodal therapy. J Obstet Gynaecol Res 2011; 37: 1731-1733.
8. Goel N, Malik R, Rathi B, et al. Pregnancy with metastatic gastrointestinal stromal tumor (GIST) on imatinib chemotherapy: an oncologist ' s nightmare and obstetrician's dilemma. J Gastrointest Cancer 2013; 44: 115-117.
9. Tsuzuki M, Inaguma Y, Handa K, et al. Successful pregnancYin a patient with chronic myeloid leukemia under treatment with imatinib. Intern Med 2009; 48: 1433-1435.
10. Conchon M, Sanabani SS, Bendit I, et al. Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol 2009; 2: 42.
11. Ault P, Kantarjian H, O'Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006; 24: 1204-1208.
12. Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood 2008; 111: 5505-5508.
13. A ziz Z, I qbal J, B ano K, et al. Sustained superior long-term outcomes and cytogenetic responses with imatinib mesylate in chronic phase chronic myeloid leukaemia: report from a developing country. Jpn J Clin Oncol 2010; 40: 549-555.
14. Aziz Z, Iqbal J, Aaqib M, et al. Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 2011; 52: 1017-1023.
15. Aziz Z, Iqbal J, Akram M, et al. Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country. Cancer 2007; 109: 1138-1145.